<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03456466</url>
  </required_header>
  <id_info>
    <org_study_id>TQB2303-I-01</org_study_id>
    <nct_id>NCT03456466</nct_id>
  </id_info>
  <brief_title>Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Parallel Control Clinical Trial to Assess the Similarity of the Safety and Pharmacokinetics of TQB2303 in Combination With Rituximab to Patients With AggressiveCD20 Positive Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Outcome Measures:&#xD;
&#xD;
      Area under the curve (AUC) forTQB2303 and rituximab concentrations [ Time Frame: 85 days ]&#xD;
&#xD;
      Secondary Outcome Measures:&#xD;
&#xD;
      The Maximum Concentration (Cmax) of the TQB2303 and rituximab [ Time Frame: 85 days ] The&#xD;
      area under the plasma concentration-time curve from 0 to inf (infinite) time (AUC0-∞); The&#xD;
      time to reach the maximum plasma concentration after treatment (Tmax) Total clearance (CL);&#xD;
      Elimination of half-life (t1 / 2); Apparent distribution volume (Vd).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>TQB2303 and Rituximab</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>85 days</time_frame>
    <description>Area under the curve (AUC) forTQB2303 and rituximab concentrations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>85 days</time_frame>
    <description>The Maximum Concentration (Cmax) of the TQB2303 and rituximab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>85 days</time_frame>
    <description>The area under the plasma concentration-time curve from 0 to inf (infinite) time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>85 days</time_frame>
    <description>The time to reach the maximum plasma concentration after treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL</measure>
    <time_frame>85 days</time_frame>
    <description>Total clearance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2</measure>
    <time_frame>85 days</time_frame>
    <description>Elimination of half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vd</measure>
    <time_frame>85 days</time_frame>
    <description>Apparent distribution volume</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of immunogenicity</measure>
    <time_frame>85 days</time_frame>
    <description>Anti-drug antibody (ADA), neutralizing antibody (Nab detection when ADA positive)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of CD19+ CD20+ B-cells from baseline</measure>
    <time_frame>85 days</time_frame>
    <description>Change of CD19+ CD20+ B-cells from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Non-hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>TQB2303</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQB2303</intervention_name>
    <description>375mg/m2 ，iv</description>
    <arm_group_label>TQB2303</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375mg/m2 ，iv</description>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients should participate in the study voluntarily and sign informed consent;&#xD;
&#xD;
          2. CD20-positive non-Hodgkin's lymphoma (NHL)：Diffuse Large B-cell Lymphoma；Mantle Cell&#xD;
             Lymphoma；Follicular Lymphoma；Marginal Zone Lymphoma;&#xD;
&#xD;
          3. having obtained CR (complete remission) or CRu (uncertain complete remisson) after the&#xD;
             prior therapy;And the investigators believe that CD20-positive B-cell NHL patients can&#xD;
             benefit from anti-CD20 monoclonal antibody therapy;&#xD;
&#xD;
          4. aged from 18 to 75 years;&#xD;
&#xD;
          5. ECOG PS:0-1；&#xD;
&#xD;
          6. Life expectancy of more than 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Had received rituximab or other anti-CD20(+) monoclonal antibody treatment within 1&#xD;
             year before enrollment;&#xD;
&#xD;
          2. patients who were treated with antitumor therapy (including corticosteroid therapy)&#xD;
             within 4 weeks prior to enrollment, or who had not recovered from the toxicity of the&#xD;
             previous treatment;&#xD;
&#xD;
          3. Patients who participated in other clinical studies within 30 days ;&#xD;
&#xD;
          4. Serious hematologic dysfunction (white blood cell count of &lt;3.0×10^9/L; absolute&#xD;
             neutrophil count of &lt;1.5×10^9/L; platelet count of &lt; 75×10^9/L; hemoglobin level of&#xD;
             &lt;80g/L); In the absence of anticoagulant therapy, International Standardization Ratio&#xD;
             (INR)&gt; 1.5× ULN;Partial prothrombin time (PTT)Or activated partial thromboplastin time&#xD;
             (aPTT)&gt; 1.5 × ULN;) Hepatic dysfunction (total bilirubin level of &gt; 1.5 × upper limit&#xD;
             of normal (ULN); aspartate amino transferase (AST) and alanine amino transferase (ALT)&#xD;
             levels of &gt; 2.0 × ULN;) renal dysfunction (serum creatinine level of &gt; 1.5×ULN );&#xD;
&#xD;
          5. Other invasive malignancies except for cured the IB or lower level of cervical cancer;&#xD;
             Non-invasive basal cells or squamous cell skin cancer; Get CR&gt; 10 years of breast&#xD;
             cancer;Get CR&gt; 10 years of malignant melanoma;or other malignancies with CR&gt; 5 years;&#xD;
&#xD;
          6. Central nervous system (CNS) lymphoma, AIDS-associated lymphoma;&#xD;
&#xD;
          7. Active infections and other serious non-malignant tumor diseases, Such as Qualitative&#xD;
             pneumonia, Severe organic cardiovascular disease, Heart conduction block &gt;&#xD;
             2,Myocardial infarction in 6 months, Cerebral infarction in 3 months,Cerebral&#xD;
             hemorrhage,Thyroid dysfunction (TSH lower than the normal lower limit or higher than&#xD;
             the upper limit of normal, and the researchers have a clinical significance);&#xD;
&#xD;
          8. Seropositive for HIV , HCV antibody; Or one of the following HBV findings :&#xD;
&#xD;
               1. HBsAg positive;&#xD;
&#xD;
               2. HBsAg negative, HBcAb positive and HBV DNA positive;&#xD;
&#xD;
          9. Plan major surgery, or surgical wound unhealed patients;&#xD;
&#xD;
         10. History of severe allergies, protein products and mouse products such as allergies;&#xD;
&#xD;
         11. Pregnancy or breast feeding. Companion for women of childbearing age or women of&#xD;
             childbearing age,who reluctant to take appropriate contraceptive methods within one&#xD;
             year after the last treatment of the study;Pregnancy before pregnancy screening, the&#xD;
             women who blood / urine results were positive;&#xD;
&#xD;
         12. Receipt of a live/attenuated vaccine within 4 weeks prior to the Screening Visit;&#xD;
&#xD;
         13. Researchers think that do not fit into the group.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jiangsu Cancer Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jifeng feng, doctor</last_name>
      <phone>025-83233303</phone>
      <email>fjif@vip.sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Suzhou University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Depei wu, doctor</last_name>
      <phone>0512-67780040</phone>
      <email>drwudepei@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>December 23, 2017</study_first_submitted>
  <study_first_submitted_qc>March 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2018</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

